

Patientforeningen Lungekræft  
 Industrivej 21  
 4000 Roskilde  
 Denmark

24 October 2024

**Participation in the Boehringer Ingelheim Patient Summit of  
 Lisbeth Søbæk Hansen**

Dear Lisbeth Søbæk Hansen,

At our invitation, the above listed Representatives of your organization (“Representatives”) will participate in the Patient Summit (“Event”) from 29-31 October, that will take place in Stockholm, Sweden. The Event aims to bringing together patient advocates and representatives of patient organizations to jointly develop solutions and exchange insights which will provide value for patients.

A brief overview of the agenda is included below:

<b>Date</b>	<b>Summary</b>
29 October 2024	<ul style="list-style-type: none"> <li>Welcome dinner and introductions to each other and the program</li> </ul>
30 October 2024	<ul style="list-style-type: none"> <li>Plenary sessions</li> <li>Workshops identifying and addressing unmet needs together with your peers across different conditions</li> </ul>
31 October 2024	<ul style="list-style-type: none"> <li>Presentations</li> <li>Workshops identifying and addressing unmet needs together with your peers from similar and adjacent conditions</li> </ul>

The solutions co-created at the Event will be taken forward by Patient Advocacy Groups, Boehringer Ingelheim or both in collaboration to empower patients and caregivers across the regions to solve the key challenges identified at the Event. Your Representatives’ role and the exchange in this workshop are critical to bring the community’s perspective to this year’s summit and to exchange insights. We look forward to your involvement and fruitful interactions.

**1. Registration**

Your Representatives have registered to the event and have provided information regarding their interest for the summit as well as some other logistical aspects such as personal requirements. Please rest assured that all information will be treated in the strictest confidence and in line with Boehringer Ingelheim’s Privacy Policy (<https://www.boehringer-ingelheim.com/data-privacy>).

**Boehringer Ingelheim B.V.**

Ref: EM-0000181057

**Deepa Maas, Patient  
 Engagement Manager**  
 Tel +31(0) 38227748  
 E-Mail  
[deepa.maas@boehringer-  
 ingelheim.com](mailto:deepa.maas@boehringer-ingelheim.com)

Basisweg 10,  
 1043 AP Amsterdam  
 Tel +31(0) 20 799 69 50  
[www.boehringer-  
 ingelheim.nl](http://www.boehringer-ingelheim.nl)

Amsterdam

### Photos and filming

The Representatives have been asked to confirm whether they are happy for photos and recordings of themselves to be taken at the Event. Please note that their decision will not affect your attendance or participation in the Event itself.

## 2. Travel and hospitality costs

In line with the nature of the collaboration, no honoraria are paid by Boehringer Ingelheim for the participation of the Representatives in the Event. We will cover the following hospitality costs for their participation in accordance with applicable laws and regulations:

<b>Travel</b>	We will book the flights (economy class) for each Representative. Details see below.
<b>Accommodation</b>	We have booked a room for each Representative in Nordic Light Hotel for 2 nights. Details see below.
<b>Meals</b>	1 <sup>st</sup> day: Dinner. 2 <sup>nd</sup> day: Breakfast, Lunch, Dinner. 3 <sup>rd</sup> day: Breakfast, Lunch.

### Your Travel Details

<b>Name of Representative</b>	<b>Outward travel</b>	<b>Return travel</b>
<b>Lisbeth Søbæk Hansen</b>	Date: 29 Oct. 2024 Airline: Scandinavian Airlines From: Copenhagen, Denmark To: Stockholm, Sweden	Date: 31 Oct. 2024 Airline: Scandinavian Airlines From: Stockholm, Sweden To: Copenhagen, Denmark

### Accommodation

We have booked a room for each Representative in Nordic Light Hotel, Vasaplan 7, 111 20 Stockholm, Sweden. The room is booked from 29<sup>th</sup> Oct. to 31<sup>st</sup> Oct, 2024.

The cost for ground transportation to and from the airport (taxi or train) can be compensated by Boehringer Ingelheim. Please keep the original copies of the invoices. Please provide a copy of invoices, a bank account confirmation letter of the payee, and the completed reimbursement form provided by CWT, and please send them to [boehringer@mycwt.pt](mailto:boehringer@mycwt.pt). Please note that Boehringer Ingelheim cannot reimburse such expenses without the copy of the invoice.

Personal costs that the Representatives incur during the stay at the Hotel, such as communication, refreshment, self-organized excursions, etc., are at their own expense.

### 3. Transparency

The transparency principle in this regard is related to payment of travel and accommodation costs, according to local law, local codes, EFPIA Code (<https://www.efpia.eu/relationships-code/the-efpia-code/>).

You agree that Boehringer Ingelheim discloses in the required registries the relationship between the Patient Organization and Boehringer Ingelheim, including any payments made to you.

Boehringer Ingelheim has implemented suitable technical and organizational measures to safeguard the processing of information in regards with transparency disclosure.

We can cancel our support to the Event for any reason including but not limited to by reason of a force majeure event. We will notify you of the cancellation as soon as possible.

Should you have any question, do not hesitate to contact Ms. Margaret Chow at [margaret.chow@boehringer-ingelheim.com](mailto:margaret.chow@boehringer-ingelheim.com).

Yours sincerely,

**Mogana Sivalingam**  
**Head of Medicine MIDI**  
**Boehringer Ingelheim B.V.**

Signature:   
CF7B56D8BBAE9422...

**Dana Leskova**  
**CMD MIDI**  
**Boehringer Ingelheim B.V.**

Signature:   
EB2CBA814D654AD...

Date: 24-Oct-2024

Date: 24-Oct-2024

**Lisbeth Søbæk Hansen**  
**Chairman**  
**Patientforeningen Lungekræft**

Signature:   
4019BC982AC8426...

Date: 25-okt-2024

## Certifikat for færdiggørelse

Kuvert-id: 5F609310A1B04245A1831E9493121ACA

Status: Gennemført

Emne: Complete with DocuSign: Patientforeningen Lungekræft\_HospitalityAgreement

Kildekuvert:

Dokumentsider: 3

Underskrifter: 3

Kuvertskaber:

Certifikatsider: 4

Initialer: 0

Margaret Ting Chow

Autonavigation: Aktiveret

Binger Straße 173

Kuvertstempling: Aktiveret

Ingelheim, Rheinland-Pfalz CT 55216

Tidszone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna

margaret.chow@boehringer-ingelheim.com

IP-adresse: 213.208.230.130

## Sporing af poster

Status: Original

Ihændeager: Margaret Ting Chow

Sted: DocuSign

24-10-2024 15:17:41

margaret.chow@boehringer-ingelheim.com

## Hændelser for underskriver

## Underskrift

## Tidsstempel

Dana Leskova

dana.leskova@boehringer-ingelheim.com

FAD MIDI

Boehringer Ingelheim

Sikkerhedsniveau: E-mail, Kontogodkendelse (ingen)

DocuSigned by:

Dana Leskova

EB2CBA814D654AD...

Sendt: 24-10-2024 15:34:40

Vist: 24-10-2024 21:53:43

Signeret: 24-10-2024 21:53:49

Vælg underskrift: Forudvalgt stil

Brug af IP-adresse: 94.209.34.229

## Oplysninger om elektroniske poster og underskrifter:

Accepteret: 18-10-2024 13:27:31

Id: ffaf6f99-1d90-4e59-b934-e4cb116bb35d

Lisbeth Søbæk Hansen

info@lungekraeft.com

Sikkerhedsniveau: E-mail, Kontogodkendelse (ingen)

Signed by:

Lisbeth Søbæk Hansen

4019BC982AC8426...

Sendt: 24-10-2024 15:34:39

Gensendt: 24-10-2024 15:40:57

Vist: 24-10-2024 16:17:09

Signeret: 25-10-2024 11:09:33

Vælg underskrift: Forudvalgt stil

Brug af IP-adresse: 62.199.46.153

## Oplysninger om elektroniske poster og underskrifter:

Accepteret: 24-10-2024 16:17:09

Id: 053d229b-8fba-4176-bb3c-b35404122fda

Mogana Sivalingam

mogana.sivalingam@boehringer-ingelheim.com

Head of Medicine MIDI

Boehringer Ingelheim Pharma GmbH &amp; Co. KG

Sikkerhedsniveau: E-mail, Kontogodkendelse (ingen)

DocuSigned by:

Mogana Sivalingam

CF7B56D98BAE9422...

Sendt: 24-10-2024 15:34:39

Vist: 24-10-2024 15:56:52

Signeret: 24-10-2024 15:56:58

Vælg underskrift: Underskrevet på enhed

Brug af IP-adresse: 213.208.230.130

## Oplysninger om elektroniske poster og underskrifter:

Accepteret: 17-10-2024 10:57:03

Id: 9c6bd58a-b8c2-4fa2-8c8c-024928903a5d

## Hændelser for personlig underskriver

## Underskrift

## Tidsstempel

## Hændelser for redaktørlevering

## Status

## Tidsstempel

## Hændelser for agentlevering

## Status

## Tidsstempel

## Hændelser for midlertidig levering

## Status

## Tidsstempel

## Hændelser for certificeret levering

## Status

## Tidsstempel

Hændelser for kopi (cc:)	Status	Tidsstempel
Lisbeth Søbæk Hansen info@lungekraeft.com Sikkerhedsniveau: E-mail, Kontogodkendelse (ingen)	<b>Kopieret</b>	Sendt: 25-10-2024 11:09:34
<b>Oplysninger om elektroniske poster og underskrifter:</b> Accepteret: 24-10-2024 16:17:09 Id: 053d229b-8fba-4176-bb3c-b35404122fda		

Vidnehændelser	Underskrift	Tidsstempel
Notarhændelser	Underskrift	Tidsstempel

Hændelser for kuvertoversigt	Status	Tidsstempler
Kuvert sendt	Med hash/krypteret	24-10-2024 15:34:40
Kuvert opdateret	Sikkerhedskontrolleret	24-10-2024 15:40:56
Leveret certificeret	Sikkerhedskontrolleret	24-10-2024 15:56:52
Signering fuldført	Sikkerhedskontrolleret	24-10-2024 15:56:58
Gennemført	Sikkerhedskontrolleret	25-10-2024 11:09:34

Betalingshændelser	Status	Tidsstempler
<b>Oplysninger om elektroniske poster og underskrifter</b>		

**Attention Boehringer employees:** If you are signing from a country that is not your country of employment, you are not allowed to sign binding agreements with external parties (e.g. speaker agreements, sponsoring agreements or consultancy agreements. Workaround: Please forward the envelope to an authorized signatory in your country of employment). This rule does not apply to the following groups: i) All employees for country combination Germany / USA. ii) AH + Group Function employees for country combination Germany / France.

## **Boehringer Ingelheim**

### **Consent to Proceed with Electronic Signatures**

This document describes the frame conditions with regard to the use of the DocuSign® system by the authorized user ('you') for electronic signing and/or processing of documents concerning the business with Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany or any of its affiliated companies ('we, us or Company').

Via the DocuSign® system, you will be able to complete, review, and even print documents you will electronically sign using only your web browser via the link sent to you by e-mail. Before using the DocuSign® system, please make sure that you are able to meet the technical system requirements, which can be accessed via the DocuSign® website. Please read the information below carefully and thoroughly.

#### **Contractual documents and notices may be sent to you electronically**

If not otherwise agreed in a given contract between you and us, we will provide electronically to you through your DocuSign® user account all contractual documents, notices and other documents that are required to be provided or made available to you during the course of our business relationship with you. To reduce the chance of you inadvertently not receiving any notice or document, we will provide all of the required notices and documents to you by the contractually agreed method(s) and to the address(es) provided therein. Subject to the provisions of the given contract you may receive documents and notices electronically or in paper format.

#### **Getting paper copies**

As long as you are an authorized user of the DocuSign® system, you will have the ability to download and print any documents we send to you through your DocuSign® user account for a limited period of time (usually 30 calendar days) after such documents are first sent to you. In case a mandatory local legal requirements exists, we will provide paper copies of the contractual documents upon your request which has to be sent to the respective Company contact nominated in the contract.

#### **Consequences of changing your mind**

In exceptional cases (f.e. contractually agreed option, mandatory local legal requirement) you may be entitled to elect to receive required notices and disclosures only or additionally in paper format. If you decide to exercise a given option you have to liaise with your respective Company contact nominated in the contract by using the address(es) in accordance with the process contractually foreseen.

#### **Changing your e-mail address**

If your e-mail address changes please arrange for your new e-mail address to be reflected in your DocuSign® account by following the process for changing e-mail in the DocuSign® system.

#### **Acknowledging your access and consent to receive materials electronically**

To confirm to us that you can access this information electronically, please verify that you were able to read this electronic consent and that you (i) also were able to print on paper or electronically save this disclosure for your future reference and access or that you (ii) were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access.

By checking the 'I Agree' box, I confirm that:

- I can access and read this CONSENT TO PROCEED WITH ELECTRONIC SIGNATURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and

- Until or unless I have notified my respective Company contact as described above, I consent to receive through electronic means all contractual documents, notices and other documents that are required to be provided or made available to me by the Company during the course of the business relationship with you.